Related Image: Uric acid may provide early clues to diabetic kidney disease |
(Date:11/21/2008)...ire-FirstCall/ -- Heska Corporation,(Nasdaq: HS...rk Society of,Security Analysts, 12th Annual Biot..., 2008 at 1177 Avenue of the Americas, 2nd Floor i...begin at 9:35 a.m. Eastern Time (7:35 a.m.,Mounta...d for two weeks,following the presentation throug...
(Date:11/21/2008)...tive against Lennox-Gastaut syndrome , ,...lled Banzel (rufinamide) has been approved as a su...y called Lennox-Gastaut syndrome, the U.S. Food an...pproval was based on results of a four-month clini...pared to patients who took a placebo, those who to...
(Date:11/21/2008).../ -- NursingCenter.com, the premier site,for onli...content, has been,updated to improve the interact...Powered by Lippincott Williams & Wilkins (LWW)...viewed continuing education activities and free,a... nursing journals.,Lippincott Williams & Wilk...
(Date:11/21/2008)...Newswire-FirstCall/ -- Today, prescription drugs a...eating 88 percent of patients suffering chronic co... a chronic condition account for 96 percent of all...medical costs. A proprietary new pharmacy model d...s, Inc. (NYSE: MHS ) significantly reduces criti...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6(Date:11/20/2008)...lif., Nov. 20 Milk. It does a body...ginally thought. After years of,research, scienti...found in,cow,s milk that stimulate the body,s own...the Multimedia News Release, go to:, http://www.pr...While developing new cancer therapies, the chief s...
(Date:11/20/2008)...ss., Nov. 20 Radius Health ("Radiu...al $15 million to its second institutional financi...$82.5 million and the total amount raised since th...ing institutional investors participated in the fi...including MPM Capital, The Wellcome Trust, HealthC...
(Date:11/20/2008)...orway, November 20 The Scandinavia...has announced results of studies on its,lead anti... Washington, DC,the studies showed that the nove...ocidal effect, significantly better towards killin...s than marketed gold standard drugs. In,addition ...
(Date:11/19/2008)...tudy did not achieve statistical significance , ...l/ -- Pharmos Corporation (Nasdaq: PARS ) today ... of its topical NanoEmulsion (NE) drug delivery te...ine. , , The multi-center, randomized, doub... safety and efficacy of the Company,s 3% Diclofena...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Scientists uncover a novel mechanism that regulates carbon dioxide fixation in plants 2389 1Scientists uncover a novel mechanism that regulates carbon dioxide fixation in plants 2389 2Surface dislocation nucleation 3A Strength is but skin deep at the nanoscale Penn engineers discover 3677 1Surface dislocation nucleation 3A Strength is but skin deep at the nanoscale Penn engineers discover 3677 2Viruses evolve to play by host rules according to University of Pennsylvania researchers 2387 1Viruses evolve to play by host rules according to University of Pennsylvania researchers 2387 2Ronnie B Martin DO FACOFP dist to be Inaugurated as the 55th President of the ACOFP 282008 2009 29 13349 1Ronnie B Martin DO FACOFP dist to be Inaugurated as the 55th President of the ACOFP 282008 2009 29 13349 2Ronnie B Martin DO FACOFP dist to be Inaugurated as the 55th President of the ACOFP 282008 2009 29 13349 3...RORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - ...ase II clinical study of its,Topical Interferon Al...nduced low-grade cervical lesions. , The study sho...,in nearly half of the treated patients. In additi...rofile, with no significant local,intolerance or d...
...Shows Strong Immune Response, Protection,Against H...07 /PRNewswire-FirstCall/ -- Novavax,Inc.,s virus-...mune,response and provided protection against the ...clinical data published in the online,edition of t... in three animal models, including,the ferret, whi...
Other Medicine Technology:Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 2Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 3Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 4Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 5Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 6Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data,Show 2Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data,Show 3Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data,Show 4...r., ,Offers an average 5:1 increase in usage time... cannula. , ,The combination of the OXYMATIC cons...oxygen patients a superior alternative to liquid o.... , ,NOTE: Each model has passed the ASTM PS ...
...r., ,Offers an average 5:1 increase in usage time... cannula. , ,The combination of the OXYMATIC cons...oxygen patients a superior alternative to liquid o.... , ,NOTE: Each model has passed the ASTM PS ...
...r., ,Offers an average 5:1 increase in usage time... cannula. , ,The combination of the OXYMATIC cons...oxygen patients a superior alternative to liquid o.... , ,NOTE: Each model has passed the ASTM PS ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!
Medicine Products: